Display options
Cite
Sun YX, Feng Q, Wang SW, et al. HLA-G-ILT2 interaction contributes to suppression of bone marrow B cell proliferation in acquired aplastic anemia. Ann Hematol. 2022;doi: 10.1007/s00277-022-04757-3.
Sun, Y. X., Feng, Q., Wang, S. W., Li, X., Sheng, Z., & Peng, J. (2022). HLA-G-ILT2 interaction contributes to suppression of bone marrow B cell proliferation in acquired aplastic anemia. Annals of hematology, . https://doi.org/10.1007/s00277-022-04757-3
Sun, Yuan-Xin, et al. "HLA-G-ILT2 interaction contributes to suppression of bone marrow B cell proliferation in acquired aplastic anemia." Annals of hematology vol. (2022). doi: https://doi.org/10.1007/s00277-022-04757-3
Sun YX, Feng Q, Wang SW, Li X, Sheng Z, Peng J. HLA-G-ILT2 interaction contributes to suppression of bone marrow B cell proliferation in acquired aplastic anemia. Ann Hematol. 2022 Jan 18; doi: 10.1007/s00277-022-04757-3. Epub 2022 Jan 18. PMID: 35041051.
Copy Download .nbib Format: NLM
Share it on

Ann Hematol. 2022 Jan 18; doi: 10.1007/s00277-022-04757-3. Epub 2022 Jan 18.

HLA-G-ILT2 interaction contributes to suppression of bone marrow B cell proliferation in acquired aplastic anemia.

Annals of hematology

Yuan-Xin Sun, Qi Feng, Shu-Wen Wang, Xin Li, Zi Sheng, Jun Peng

Affiliations

  1. Department of Hemodialysis, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
  2. Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
  3. Shandong Provincial Key Laboratory of Immunohematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
  4. Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China. [email protected].
  5. School of Medicine, Cheeloo College of Medicine, Shandong University, Jinan, China. [email protected].
  6. Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China. [email protected].
  7. State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China. [email protected].

PMID: 35041051 DOI: 10.1007/s00277-022-04757-3

Abstract

Acquired aplastic anemia (AA) is an autoimmune disease characterized by hematopoietic stem and progenitor cell destruction in bone marrow. The non-classic human leukocyte class I antigen (HLA-) G interacts with multiple cell subsets, such as T cells and B cells. HLA-G exerts powerful immune suppression by binding with its receptors, immunoglobulin-like transcripts (ILTs). Here, we compared 46 AA patients and 28 healthy controls. Soluble HLA-G levels in bone marrow supernatants from AA patients were higher than controls. The proportion of bone marrow B cells was decreased and the ILT2-expressing cells among CD19

© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Keywords: Aplastic anemia; Bone marrow B cells; HLA-G; ILT2

References

  1. de Latour RP, Visconte V, Takaku T, Wu C, Erie AJ, Sarcon AK, Desierto MJ, Scheinberg P, Keyvanfar K, Nunez O, Chen J, Young NS (2010) Th17 immune responses contribute to the pathophysiology of aplastic anemia. Blood 116(20):4175–4184. https://doi.org/10.1182/blood-2010-01-266098 - PubMed
  2. Young NS (2013) Current concepts in the pathophysiology and treatment of aplastic anemia. Hematology Am Soc Hematol Educ Program 2013:76–81. https://doi.org/10.1182/asheducation-2013.1.76 - PubMed
  3. Shi J, Ge M, Lu S, Li X, Shao Y, Huang J, Huang Z, Zhang J, Nie N, Zheng Y (2012) Intrinsic impairment of CD4(+)CD25(+) regulatory T cells in acquired aplastic anemia. Blood 120(8):1624–1632. https://doi.org/10.1182/blood-2011-11-390708 - PubMed
  4. Zeng Y, Katsanis E (2015) The complex pathophysiology of acquired aplastic anaemia. Clin Exp Immunol 180(3):361–370. https://doi.org/10.1111/cei.12605 - PubMed
  5. Hirano N, Butler MO, Von Bergwelt-Baildon MS, Maecker B, Schultze JL, O’Connor KC, Schur PH, Kojima S, Guinan EC, Nadler LM (2003) Autoantibodies frequently detected in patients with aplastic anemia. Blood 102(13):4567–4575. https://doi.org/10.1182/blood-2002-11-3409 - PubMed
  6. Feng X, Chuhjo T, Sugimori C, Kotani T, Lu X, Takami A, Takamatsu H, Yamazaki H, Nakao S (2004) Diazepam-binding inhibitor-related protein 1: a candidate autoantigen in acquired aplastic anemia patients harboring a minor population of paroxysmal nocturnal hemoglobinuria-type cells. Blood 104(8):2425–2431. https://doi.org/10.1182/blood-2004-05-1839 - PubMed
  7. Goto M, Kuribayashi K, Takahashi Y, Kondoh T, Tanaka M, Kobayashi D, Watanabe N (2013) Identification of autoantibodies expressed in acquired aplastic anaemia. Br J Haematol 160(3):359–362. https://doi.org/10.1111/bjh.12116 - PubMed
  8. Hirano N, Butler MO, Guinan EC, Nadler LM, Kojima S (2005) Presence of anti-kinectin and anti-PMS1 antibodies in Japanese aplastic anaemia patients. Br J Haematol 128(2):221–223. https://doi.org/10.1111/j.1365-2141.2004.05317.x - PubMed
  9. Takamatsu H, Feng X, Chuhjo T, Lu X, Sugimori C, Okawa K, Yamamoto M, Iseki S, Nakao S (2007) Specific antibodies to moesin, a membrane-cytoskeleton linker protein, are frequently detected in patients with acquired aplastic anemia. Blood 109(6):2514–2520. https://doi.org/10.1182/blood-2006-07-036715 - PubMed
  10. Hao S, Zhang Y, Hua L, Xie N, Xiao N, Wang H, Fu R, Shao Z (2020) Antibodies specific to ferritin light chain polypeptide are frequently detected in patients with immunerelated pancytopenia. Mol Med Rep 22(3):2012–2020. https://doi.org/10.3892/mmr.2020.11280 - PubMed
  11. Qi Z, Takamatsu H, Espinoza JL, Lu X, Sugimori N, Yamazaki H, Okawa K, Nakao S (2010) Autoantibodies specific to hnRNP K: a new diagnostic marker for immune pathophysiology in aplastic anemia. Ann Hematol 89(12):1255–1263. https://doi.org/10.1007/s00277-010-1020-3 - PubMed
  12. Curigliano G, Criscitiello C, Gelao L, Goldhirsch A (2013) Molecular pathways: human leukocyte antigen G (HLA-G). Clin Cancer Res 19(20):5564–5571. https://doi.org/10.1158/1078-0432.CCR-12-3697 - PubMed
  13. Carosella ED, Favier B, Rouas-Freiss N, Moreau P, Lemaoult J (2008) Beyond the increasing complexity of the immunomodulatory HLA-G molecule. Blood 111(10):4862–4870. https://doi.org/10.1182/blood-2007-12-127662 - PubMed
  14. LeMaoult J, Zafaranloo K, Le Danff C, Carosella ED (2005) HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells. FASEB J 19(6):662–664. https://doi.org/10.1096/fj.04-1617fje - PubMed
  15. Bahri R, Hirsch F, Josse A, Rouas-Freiss N, Bidere N, Vasquez A, Carosella ED, Charpentier B, Durrbach A (2006) Soluble HLA-G inhibits cell cycle progression in human alloreactive T lymphocytes. J Immunol 176(3):1331–1339. https://doi.org/10.4049/jimmunol.176.3.1331 - PubMed
  16. Caumartin J, Favier B, Daouya M, Guillard C, Moreau P, Carosella ED, LeMaoult J (2007) Trogocytosis-based generation of suppressive NK cells. EMBO J 26(5):1423–1433. https://doi.org/10.1038/sj.emboj.7601570 - PubMed
  17. Rouas-Freiss N, Marchal RE, Kirszenbaum M, Dausset J, Carosella ED (1997) The alpha1 domain of HLA-G1 and HLA-G2 inhibits cytotoxicity induced by natural killer cells: is HLA-G the public ligand for natural killer cell inhibitory receptors? Proc Natl Acad Sci USA 94(10):5249–5254 - PubMed
  18. Contini P, Ghio M, Poggi A, Filaci G, Indiveri F, Ferrone S, Puppo F (2003) Soluble HLA-A,-B,-C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation. Eur J Immunol 33(1):125–134. https://doi.org/10.1002/immu.200390015 - PubMed
  19. Fournel S, Aguerre-Girr M, Huc X, Lenfant F, Alam A, Toubert A, Bensussan A, Le Bouteiller P (2000) Cutting edge: soluble HLA-G1 triggers CD95/CD95 ligand-mediated apoptosis in activated CD8+ cells by interacting with CD8. J Immunol 164(12):6100–6104 - PubMed
  20. Morandi F, Rouas-Freiss N, Pistoia V (2014) The emerging role of soluble HLA-G in the control of chemotaxis. Cytokine Growth Factor Rev 25(3):327–335. https://doi.org/10.1016/j.cytogfr.2014.04.004 - PubMed
  21. Ristich V, Liang S, Zhang W, Wu J, Horuzsko A (2005) Tolerization of dendritic cells by HLA-G. Eur J Immunol 35(4):1133–1142. https://doi.org/10.1002/eji.200425741 - PubMed
  22. LeMaoult J, Krawice-Radanne I, Dausset J, Carosella ED (2004) HLA-G1-expressing antigen-presenting cells induce immunosuppressive CD4+ T cells. Proc Natl Acad Sci USA 101(18):7064–7069. https://doi.org/10.1073/pnas.0401922101 - PubMed
  23. Naji A, Le Rond S, Durrbach A, Krawice-Radanne I, Creput C, Daouya M, Caumartin J, LeMaoult J, Carosella ED, Rouas-Freiss N (2007) CD3+CD4low and CD3+CD8low are induced by HLA-G: novel human peripheral blood suppressor T-cell subsets involved in transplant acceptance. Blood 110(12):3936–3948. https://doi.org/10.1182/blood-2007-04-083139 - PubMed
  24. Naji A, Menier C, Morandi F, Agaugue S, Maki G, Ferretti E, Bruel S, Pistoia V, Carosella ED, Rouas-Freiss N (2014) Binding of HLA-G to ITIM-bearing Ig-like transcript 2 receptor suppresses B cell responses. J Immunol 192(4):1536–1546. https://doi.org/10.4049/jimmunol.1300438 - PubMed
  25. Negrini S, Contini P, Pupo F, Greco M, Murdaca G, Puppo F (2020) Expression of membrane-bound human leucocyte antigen-G in systemic sclerosis and systemic lupus erythematosus. Hum Immunol 81(4):162–167. https://doi.org/10.1016/j.humimm.2019.12.004 - PubMed
  26. Rizzo R, Farina I, Bortolotti D, Galuppi E, Rotola A, Melchiorri L, Ciancio G, Di Luca D, Govoni M (2013) HLA-G may predict the disease course in patients with early rheumatoid arthritis. Hum Immunol 74(4):425–432. https://doi.org/10.1016/j.humimm.2012.11.024 - PubMed
  27. Contini P, Murdaca G, Puppo F, Negrini S (2020) HLA-G expressing immune cells in immune mediated diseases. Front Immunol 11:1613. https://doi.org/10.3389/fimmu.2020.01613 - PubMed
  28. Catamo E, Addobbati C, Segat L, Sotero Fragoso T, Domingues Barbosa A, Tavares Dantas A, de Ataide Mariz H, F da Rocha L Jr, Branco Pinto Duarte AL, Monasta L, Sandrin-Garcia P, Crovella S (2014) HLA-G gene polymorphisms associated with susceptibility to rheumatoid arthritis disease and its severity in Brazilian patients. Tissue Antigens 84(3):308–315. https://doi.org/10.1111/tan.12396 - PubMed
  29. Rizzo R, Rubini M, Govoni M, Padovan M, Melchiorri L, Stignani M, Carturan S, Ferretti S, Trotta F, Baricordi OR (2006) HLA-G 14-bp polymorphism regulates the methotrexate response in rheumatoid arthritis. Pharmacogenet Genomics 16(9):615–623. https://doi.org/10.1097/01.fpc.0000230115.41828.3a - PubMed
  30. Bae SC, Lee YH (2021) Association of HLA-G polymorphisms with systemic lupus erythematosus and correlation between soluble HLAG levels and the disease: a meta-analysis. Z Rheumatol 80(1):96–102. https://doi.org/10.1007/s00393-020-00783-6 - PubMed
  31. Camitta BM, Thomas ED, Nathan DG, Santos G, Gordon-Smith EC, Gale RP, Rappeport JM, Storb R (1976) Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality. Blood 48(1):63–70 - PubMed
  32. Loken MR, Shah VO, Hollander Z, Civin CI (1988) Flow cytometric analysis of normal B lymphoid development. Pathol Immunopathol Res 7(5):357–370 - PubMed
  33. Ghia P, ten Boekel E, Rolink AG, Melchers F (1998) B-cell development: a comparison between mouse and man. Immunol Today 19(10):480–485 - PubMed
  34. Li X, Xu F, He Q, Wu L, Zhang Z, Chang C (2010) Comparison of immunological abnormalities of lymphocytes in bone marrow in myelodysplastic syndrome (MDS) and aplastic anemia (AA). Intern Med 49(14):1349–1355 - PubMed
  35. Naji A, Menier C, Maki G, Carosella ED, Rouas-Freiss N (2012) Neoplastic B-cell growth is impaired by HLA-G/ILT2 interaction. Leukemia 26(8):1889–1892. https://doi.org/10.1038/leu.2012.62 - PubMed
  36. Lamar DL, Weyand CM, Goronzy JJ (2010) Promoter choice and translational repression determine cell type-specific cell surface density of the inhibitory receptor CD85j expressed on different hematopoietic lineages. Blood 115(16):3278–3286. https://doi.org/10.1182/blood-2009-09-243493 - PubMed
  37. Banham AH, Colonna M, Cella M, Micklem KJ, Pulford K, Willis AC, Mason DY (1999) Identification of the CD85 antigen as ILT2, an inhibitory MHC class I receptor of the immunoglobulin superfamily. J Leukoc Biol 65(6):841–845 - PubMed

Publication Types

Grant support